Wall Street analysts predict that Inogen, Inc (NASDAQ:INGN) will announce sales of $61.97 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Inogen’s earnings. The lowest sales estimate is $61.59 million and the highest is $62.20 million. Inogen reported sales of $50.85 million during the same quarter last year, which would suggest a positive year over year growth rate of 21.9%. The business is scheduled to issue its next earnings report on Tuesday, February 27th.

According to Zacks, analysts expect that Inogen will report full year sales of $61.97 million for the current financial year, with estimates ranging from $242.00 million to $247.80 million. For the next fiscal year, analysts expect that the firm will report sales of $302.19 million per share, with estimates ranging from $300.10 million to $304.27 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover Inogen.

Inogen (NASDAQ:INGN) last issued its quarterly earnings data on Tuesday, November 7th. The medical technology company reported $0.33 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.29 by $0.04. Inogen had a net margin of 11.36% and a return on equity of 13.37%. The business had revenue of $69.00 million during the quarter, compared to analyst estimates of $63.55 million. During the same period last year, the business posted $0.25 earnings per share. Inogen’s quarterly revenue was up 26.8% compared to the same quarter last year.

INGN has been the subject of several recent research reports. Needham & Company LLC reiterated a “buy” rating and set a $108.00 target price on shares of Inogen in a report on Friday, September 1st. Piper Jaffray Companies reiterated a “hold” rating and set a $90.00 target price on shares of Inogen in a report on Tuesday, September 12th. BidaskClub lowered shares of Inogen from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Zacks Investment Research upgraded shares of Inogen from a “hold” rating to a “buy” rating and set a $131.00 target price for the company in a report on Thursday. Finally, Leerink Swann reiterated an “outperform” rating and set a $120.00 target price (up from $115.00) on shares of Inogen in a report on Wednesday, November 8th. Three research analysts have rated the stock with a hold rating, three have given a buy rating and two have assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $103.14.

In related news, EVP Matt Scribner sold 2,500 shares of the business’s stock in a transaction that occurred on Friday, August 18th. The shares were sold at an average price of $92.45, for a total value of $231,125.00. Following the completion of the transaction, the executive vice president now directly owns 6,964 shares in the company, valued at approximately $643,821.80. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Raymond Huggenberger sold 14,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $91.67, for a total transaction of $1,283,380.00. Following the completion of the transaction, the director now owns 7,808 shares of the company’s stock, valued at $715,759.36. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 67,000 shares of company stock valued at $6,424,010. 5.31% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in INGN. Schroder Investment Management Group purchased a new position in Inogen in the 2nd quarter worth approximately $132,000. Ameritas Investment Partners Inc. grew its position in Inogen by 6.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,495 shares of the medical technology company’s stock worth $143,000 after purchasing an additional 86 shares during the period. Sei Investments Co. grew its position in Inogen by 38.1% in the 2nd quarter. Sei Investments Co. now owns 1,606 shares of the medical technology company’s stock worth $153,000 after purchasing an additional 443 shares during the period. Victory Capital Management Inc. grew its position in Inogen by 17.8% in the 2nd quarter. Victory Capital Management Inc. now owns 2,036 shares of the medical technology company’s stock worth $194,000 after purchasing an additional 307 shares during the period. Finally, Pinebridge Investments L.P. grew its position in Inogen by 1.6% in the 2nd quarter. Pinebridge Investments L.P. now owns 2,143 shares of the medical technology company’s stock worth $204,000 after purchasing an additional 33 shares during the period.

Shares of Inogen (NASDAQ:INGN) opened at $114.19 on Monday. Inogen has a 1-year low of $59.84 and a 1-year high of $124.90. The company has a market cap of $2,383.19, a PE ratio of 92.84, a price-to-earnings-growth ratio of 4.80 and a beta of 0.99.

TRADEMARK VIOLATION NOTICE: This piece of content was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/11/13/inogen-inc-ingn-expected-to-announce-quarterly-sales-of-61-97-million.html.

Inogen Company Profile

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Get a free copy of the Zacks research report on Inogen (INGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Inogen (NASDAQ:INGN)

Receive News & Stock Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related stocks with our FREE daily email newsletter.